-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pyruvate kinase deficiency is a rare, hereditary, chronic disease associated with hemolytic anemia
Announced on February 17, the U.
In this global, randomized, placebo-controlled Phase 3 clinical trial, researchers evaluated the efficacy and safety of Mitapivat in adult patients with pyruvate kinase deficiency who were not receiving normal red blood cell transfusions
The Phase 3 ACTIVATE trial of mitapivat met its primary endpoint
Jaundice (LS mean difference PYRUKYND minus placebo: -0.
The most common adverse events were nausea (7 patients [18%] in the Mitapivat group and 9 patients [23%] in the placebo group) and headache (6 patients [15%] and 13 patients [33%], respectively)
The most common adverse reactions in patients with PK deficiency included laboratory abnormalities (≥10%) were decreased estrone (males), increased uric acid, back pain, decreased estradiol (males), and arthralgia
CONCLUSIONS: In patients with pyruvate kinase deficiency, Mitapivat significantly increased hemoglobin levels, reduced hemolysis, and improved patient-reported outcomes .
In patients with pyruvate kinase deficiency, Mitapivat significantly increased hemoglobin levels, decreased hemolysis, and improved patient-reported outcomes
